EP0702555A1 — Pyrazolopyrimidinones for the treatment of impotence

USPTO Abstract

The use of a compound of formula (I) wherein R1 is H; C¿1?-C3 alkyl; C1-C3 perfluoroalkyl; or C3-C5 cycloalkyl; R?2¿ is H; optionally substituted C¿1?-C6 alkyl; C1-C3 perfluoroalkyl; or C3-C6 cycloalkyl; R?3¿ is optionally substituted C¿1?-C6 alkyl; C1-C6 perfluoroalkyl; C3-C5 cycloalkyl; C3-C6 alkenyl; or C3-C6 alkynyl; R?4¿ is optionally substituted C¿1?-C4 alkyl, C2-C4 alkenyl, C2-C4 alkanoyl, (hydroxy)C2-C4 alkyl or (C2-C3 alkoxy)C1-C2 alkyl; CONR?5R6; CO¿2R7; halo; NR5R6; NHSO¿2NR?5R6; NHSO¿2R?8; SO2NR9R10; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R?5 and R6¿ are each independently H or C¿1?-C4 alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino, 4-N(R?11¿)-piperazinyl or imidazolyl group; R7 is H or C¿1?-C4 alkyl; R?8¿ is optionally substituted C¿1?-C3 alkyl; R?9 and R10¿ together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino or 4-N(R12)-piperazinyl group; R11 is H; optionally substituted C¿1?-C3 alkyl; (hydroxy)C2-C3 alkyl; or C1-C4 alkanoyl; R?12¿ is H; optionally substituted C¿1?-C6 alkyl; CONR?13R14; CSNR13R14¿; or C(NH)NR?13R14; and R13? and R?14¿ are each independently H; C¿1?-C4 alkyl; or substituted C2-C4 alkyl; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said male animal with said pharmaceutical composition or with said either entity.